[A26-78] Venetoclax (previously untreated chronic lymphocytic leukaemia; combination with acalabrutinib with or without obinutuzumab) – Benefit assessment according to §35a Social Code Book V
Last updated 23.09.2026
Project no.:
A26-78
Commission:
Commission awarded on 01.07.2026 by the Federal Joint Committee (GBA).
Report type:
Dossier assessment
Status:
Commission work started
Department/Division:
Drug Assessment
Topic:
Cancer
| Project no. | Title | Status |
|---|---|---|
| A18-81 | Venetoclax (chronic lymphocytic leukaemia) - Benefit assessment according to §35a Social Code Book V | Commission completed |
| A18-82 | Venetoclax (chronic lymphocytic leukaemia) - Benefit assessment according to §35a Social Code Book V | Commission completed |
| A20-39 | Venetoclax (chronic lymphocytic leukaemia) - Benefit assessment according to §35a Social Code Book V | Commission completed |
| A21-81 | Upadacitinib (psoriatic arthritis) - Addendum to Commission A21-15 | Commission completed |
| A26-77 | Venetoclax (chronic lymphocytic leukaemia) – Benefit assessment according to §35a Social Code Book V | Commission work started |